Compounded 17-hydroxyprogesterone caproate is an inexpensive and safe alternative to the FDA-approved product

摘要

Prematurity continues to be the major source of neonatal morbidity and mortality. Efforts to decrease the risk of prematurity in the past have focused on preventing contractions with tocolytics, early identification of contractions with home uterine monitoring, and predicting preterm delivery through history and biochemical evaluations. The Institute of Medicine estimated in 2005 that the average direct medical care costs for a preterm infant in the United States is $33,200, with the majority (85%) of this cost occurring in the first year of life. The cost per infant increases to $51,600 when maternal medical care costs ($3800), early intervention costs ($1203), special education costs ($2150), and lost household productivity costs ($11,215) are considered.